Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

• Status: Terminated
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare the safety and efficacy of sunitinib in combination with FOLFOX versus bevacizumab in combination with FOLFOX for the treatment of patients with metastatic colorectal cancer who have not been treated before.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Bevacizumab; Fluorouracil; Oxaliplatin; Sunitinib

Criteria

Inclusion Criteria:

• Adenocarcinoma of the colon or rectum with locally advanced or metastatic disease

• Evidence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)

• Eastern Cooperative Oncology Group (ECOG) 0 or 1

Exclusion Criteria:

• Previous treatment with Sutent, Avastin, or any other systemic therapy for locally advanced or metastatic colorectal cancer

• Less than 6 months since completion of adjuvant chemotherapy to documentation of recurrent disease

• History of cardiac disease

• Brain mets